Oncology News Central (ONC)Cancer Drug Tazemetostat Pulled Due to Safety Concerns

Ipsen voluntarily withdrew tazemetostat (Tazverik) from all markets after a confirmatory trial identified a risk of secondary hematologic malignancies. The withdrawal is effective immediately, covering all approved indications including follicular lymphoma and epithelioid sarcoma.

Professional Impact

• The SYMPHONY-1 independent data monitoring committee determined secondary malignancy risk outweighs benefit, triggering immediate global withdrawal
• Accelerated approval pathway is under scrutiny: tazemetostat’s confirmatory trial produced the safety signal that reversed its own approval
• Patients enrolled in SYMPHONY-1 will continue lenalidomide plus rituximab without tazemetostat; all other trials and expanded access programs are discontinued
• EZH2-mutated follicular lymphoma and epithelioid sarcoma patients currently on tazemetostat require urgent transition planning

Action Items

• Identify all patients currently prescribed tazemetostat and initiate transition plans immediately
• Counsel patients on the withdrawal rationale and available alternative regimens
• Document tazemetostat discontinuation and updated treatment plans in patient records
• Monitor affected patients for secondary malignancy signals given prior exposure

More Product Recalls